Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality

(2017) Michael V. Holmes et al.   Nature Reviews Cardiology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

The druggable genome and support for target identification and validation in drug development

(2017) Chris Finan et al.   Science Translational Medicine

Leveraging human genetics to guide drug target discovery

(2017) Nathan O. Stitziel et al.   TRENDS IN CARDIOVASCULAR MEDICINE

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

(2017) Amand F Schmidt et al.   Lancet Diabetes & Endocrinology

Genetically predicted 17beta-estradiol and cardiovascular risk factors in women: a Mendelian randomization analysis using young women in Hong Kong and older women in the Guangzhou Biobank Cohort Study

(2016) Shiu Lun Au Yeung et al.   ANNALS OF EPIDEMIOLOGY

Phenome-Wide Association Studies as a Tool to Advance Precision Medicine

(2016) Joshua C. Denny et al.   Annual Review of Genomics and Human Genetics

Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator

(2016) Jack Bowden et al.   GENETIC EPIDEMIOLOGY

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

(2016) Michael G. Silverman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes

(2016) Luca A. Lotta et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors

(2016) Stephen Burgess et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

The genetics of drug efficacy: opportunities and challenges

(2016) Matthew R. Nelson et al.   NATURE REVIEWS GENETICS

Unravelling the human genome–phenome relationship using phenome-wide association studies

(2016) William S. Bush et al.   NATURE REVIEWS GENETICS

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression

(2015) J. Bowden et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

(2015) Daniel I Swerdlow et al.   LANCET

Opportunities for drug repositioning from phenome-wide association studies

(2015) Majid Rastegar-Mojarad et al.   NATURE BIOTECHNOLOGY

The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans

(2015) et al.   SCIENCE

MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization

(2015) Louise A. C. Millard et al.   Scientific Reports

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis

(2015)   Lancet Diabetes & Endocrinology

Mendelian randomization: genetic anchors for causal inference in epidemiological studies

(2014) G. Davey Smith et al.   HUMAN MOLECULAR GENETICS

Narrative Review: Statin-Related Myopathy

(2013) Tisha R. Joy   ANNALS OF INTERNAL MEDICINE

Novel gene variants predict serum levels of the cytokines IL-18 and IL-1ra in older adults

(2013) A.M. Matteini et al.   CYTOKINE

Discovery and refinement of loci associated with lipid levels

(2013) Cristen J Willer et al.   NATURE GENETICS

Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis

(2012) R Harpaz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Use of genome-wide association studies for drug repositioning

(2012) Philippe Sanseau et al.   NATURE BIOTECHNOLOGY

Drug repositioning for Alzheimer's disease

(2012) Anne Corbett et al.   NATURE REVIEWS DRUG DISCOVERY

Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions

(2011) Ann K. Daly   Annual Review of Pharmacology and Toxicology

Deconstructing the Drug Development Process: The New Face of Innovation

(2010) K I Kaitin   CLINICAL PHARMACOLOGY & THERAPEUTICS

Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health

(2010) George Davey Smith   Genes and Nutrition

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Confounding Control in Healthcare Database Research

(2010) M. Alan Brookhart et al.   MEDICAL CARE

Genome-wide association studies in pharmacogenomics

(2010) Ann K. Daly   NATURE REVIEWS GENETICS

Mendelian Randomization: How It Can--and Cannot--Help Confirm Causal Relations between Nutrition and Cancer

(2009) A. Schatzkin et al.   Cancer Prevention Research

Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies

(2008) R.H.H. Groenwold et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

(2008) Sekar Kathiresan et al.   NATURE GENETICS

Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology

(2007) Debbie A. Lawlor et al.   STATISTICS IN MEDICINE